Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
Ustekinumab as first line therapeutic choice of biological therapy in bionaive patient affected with ulcerative colitis and intestinal reactivation of cytomegalovirus infection
https://doi.org/10.33667/2078-5631-2023-34-6-10
Abstract
Ulcerative colitis is a chronic autoimmune disease characterized by inflammation of colonic mucous layer. Patients affected with ulcerative colitis are often subjected to immunosuppressive therapy that makes them susceptible to opportunistic infections. This article presents clinical case of moderate-to-severe ulcerative colitis, complicated by cytomegalovirus infection. We demonstrated the necessity of the inclusion of cytomegalovirus infection into the differential diagnostic algorithm of ulcerative colitis relapse using molecular methods of diagnosis. Also, we justified the choice of specific antiviral therapy and first line biological therapy in a bionaive steroid-dependent, refractory to thiopurines patient. The choice of ustekinumab as therapeutic armamentarium showed to be safe and effective in attainment and maintenance of persistent clinical, laboratory and endoscopic remission in a patient affected with ulcerative colitis with intestinal reactivation of cytomegalovirus infection.
About the Authors
S. N. Serikova
Kuban State Medical University; Regional Clinical Hospital No. 2
Russian Federation
Russian Federation
Serikova Svetlana N., DM Sci (habil.), professor at Dept of Surgery No. 3 of Faculty of Advanced Training and Professional Retraining of Specialists; head of Gastroenterological Centre of the Polyclinic for Specialized Course of Outpatient Treatment,
Krasnodar.
N. V. Korochanskaya
Kuban State Medical University; Regional Clinical Hospital No. 2
Russian Federation
Russian Federation
Korochanskaya Natalya V., DM Sci (habil.), professor at Dept of Surgery No. 3 of Faculty of Advanced Training and Professional Retraining of Specialists; head of Gastroenterological Centre,
Krasnodar.
O. A. Usova
Regional Clinical Hospital No. 2
Russian Federation
Russian Federation
Usova Olga A., gastroenterologist at Gastroenterology Dept.,
Krasnodar.
R. A. Barcho
Regional Clinical Hospital No. 2
Russian Federation
Russian Federation
Barcho Raziet A., gastroenterologist at Gastroenterological Centre of the Polyclinic for Specialized Course of Outpatient Treatment,
Krasnodar.
E. I. Pryadko
Kuban State Medical University
Russian Federation
Russian Federation
Pryadko Ekaterina I., resident doctor,
Krasnodar.
V. A. Georgiadu
Kuban State Medical University
Russian Federation
Russian Federation
Georgiadu Violeta A., resident doctor,
Krasnodar
References
1. Шелыгин Ю.А., Ивашкин В. Т., Белоусова Е.А. и др. Клинические рекомендации. Язвенный колит (К51), взрослые 2023. Колопроктология. 2023; 22 (1): 10–44. https://doi.org/10.33878/2073–7556–2023–22–1–10–44 Shelygin Yu.A., Ivashkin V.T., Belousova E.A. and others. Clinical recommendations. Ulcerative colitis (K51), adults 2023. Coloproctology. 2023; 22 (1): 10–44. https://doi.org/10.33878/2073–7556–2023–22–1–10–44
2. Валганцикловир в рецидивирующих приступах криптогенных воспалительных заболеваний кишечника с инфекцией цитомегаловирусом: MICI–CMV. ICH GCP: Реестр клинических испытаний США. Клинические испытания NCT00237653. https://clinicaltrials.gov Valganciclovir in recurrent attacks of cryptogenic inflammatory bowel disease with cytomegalovirus infection: MICI–CMV. ICH GCP: US Clinical Trials Registry. Clinical trial NCT00237653. https://clinicaltrials.gov
3. Волчкова Е. В., Белоусова Е.А., Богомазов Ю.К. и др. Оппортунистические инфекции при воспалительных заболеваниях кишечника: цитомегаловирус – клиническое наблюдение. Фарматека для практикующих врачей. 2010; 15: 118–122. Volchkova E. V., Belousova E. A., Bogomazov Yu.K. and others. Opportunistic infections in inflammatory bowel diseases: cytomegalovirus – clinical observation. Pharmacy for Medical Practitioners. 2010; 15: 118–122.
4. Rahier J. F., Magro F., Abreu C., et al. European Crohn's and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. JCC; 2014: 8 (6): 443–468. https://doi.org/10.1016/j.crohns.2013.12.013
5. Powell R.D., Warner N.E., Levine R. S., et al. Cytomegalic inclusion disease and ulcerative colitis. Report of a case in a young adult. Am J Med. 1961; 30: 334–340. https://doi.org/10.1016/0002–9343(61)90105-x.
6. Henmi KK Y., Inoue T., et al. Cytomegalovirus infection in ulcerative colitis assessed by quantitative polymerase chain reaction: Risk factors and effects of immunosuppressants. J Clin Biochem Nutr. 2018; 63: 246–51. https://doi.org/10.3164/jcbn.18–14
7. Liu CC J.S., Ding Y., et al. Cytomegalovirus infection and steroid-refractory inflammatory bowel disease: Possible relationship from an updated meta-analysis. Ir J Med Sci. 2018; 187: 935–42. https://doi.org/10.1007/s11845–018–1752-y
8. Qin Y., Wang G., Kong D., et al. Risk Factors of Cytomegalovirus Reactivation in Ulcerative Colitis Patients: A Meta-Analysis. Diagnostics (Basel, Switzerland). 2021; 11 (11): 1952. https://doi.org/10.3390/diagnostics11111952
9. Pillet S., Pozzetto B., Roblin X. Cytomegalovirus and ulcerative colitis: Place of antiviral therapy. World J Gastroenterol. 2016; 22 (6): 2030–2045. https://doi.org/10.3748/wjg.v22.i6.2030
10. Kim Y. S., Kim Y.H., Kim J. S., et al. Long-term outcomes of cytomegalovirus reactivation in patients with moderate to severe ulcerative colitis: a multicenter study. Gut Liver. 2014; 8(6): 643–647. https://doi.org/10.5009/gnl13427
11. Kambham N., Vij R., Cartwright C.A., et al. Cytomegalovirus infection in steroid refractory ulcerative colitis: A case-control study. Am J Surg Pathol. 2004; 28 (3): 365–373. https://doi.org/10.1097/00000478–200403000–00009
12. Minami M., Ohta M., Ohkura T., et al. Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cyclosporine treatment in Japan. W J Gastroenterol. 2007; 13 (5): 754–760. https://doi.org/10.3748/wjg.v13.i5.754
13. Domenech E., Vega R., Ojanguren I., et al. Cytomegalovirus infection in ulcerative colitis: A prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis. 2008; 14 (10): 1373–1379. https://doi.org/10.1002/ibd.20498
14. Lamb C.A., Kennedy N.A., Raine T., et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019; 68: 1–106. https://doi.org/10.1136/gutjnl‑2019–318484
15. Yokoyama Y., Yamakawa T., Hirano T., et al. Current Diagnostic and Therapeutic Approaches to Cytomegalovirus Infections in Ulcerative Colitis Patients Based on Clinical and Basic Research Data. Int J Mol Sci. 2020; 21 (7): 2438. https://doi.org/10.3390/ijms21072438
16. Okahara K., Nagata N., Shimada T., et al. Colonic cytomegalovirus detection by mucosal PCR and antiviral therapy in ulcerative colitis. PloS ONE. 2017; 12: e0183951. https://doi.org/10.1371/journal.pone.0183951
17. Raine T., Bonova S., Burisch J., et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. JCC. 2022; 16(1): 2–17. https://doi.org/10.1093/ecco-jcc/jjab178
18. Shukla T., Singh S., Loftus E.V., et al. Antiviral Therapy in Steroid-refractory Ulcerative Colitis with Cytomegalovirus: Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2015; 21 (11): 2718–2725. https://doi.org/10.1097/MIB.0000000000000489
19. Jones A., McCurdy J.D., Loftus E.V., et al. Effects of antiviral therapy for patients with inflammatory bowel disease and a positive intestinal biopsy for cytomegalovirus. Clin Gastroenterol Hepatol. 2015; 13(5): 949–955. https://doi.org/10.1016/j.cgh.2014.09.042
20. Князев О.В., Лазебник Л.Б., Парфенов А.И. и др. Полная элиминация цитомегаловируса после системной трансплантации мезенхимальных стромальных клеток у больного язвенным колитом без противовирусной терапии. Терапевтический архив. 2012; 84 (12): 103–107. Knyazev O. V., Lazebnik L. B., Parfenov A. I. et al. Complete elimination of cytomegalovirus after systemic transplantation of mesenchymal stromal cells in a patient with ulcerative colitis without antiviral therapy. Therapeutic Archive. 2012; 84 (12): 103–107.
21. Белоусова Е.А., Абдулхаков Р.А., Бакулин И. Г. и др. Эффективность и безопасность устекинумаба у пациентов со среднетяжелым и тяжелым активным язвенным колитом в российской популяции: субанализ международного исследования III фазы индукционной и поддерживающей терапии (UNIFI) на протяжении 3 лет. Колопроктология. 2023; 22 (1): 54–64. https://doi.org/10.33878/2073–7556–2023–22–1–54–64 Belousova E. A., Abdulkhakov R. A., Bakulin I. G. et al. Efficacy and safety of ustekinumab in patients with moderate and severe active ulcerative colitis in the Russian population: subanalysis of the international phase III study of induction and maintenance therapy (UNIFI) over 3 years. Coloproctology. 2023; 22 (1): 54–64. https://doi.org/10.33878/2073–7556–2023–22–1–54–64
Review
For citations:
Serikova S.N., Korochanskaya N.V., Usova O.A., Barcho R.A., Pryadko E.I., Georgiadu V.A. Ustekinumab as first line therapeutic choice of biological therapy in bionaive patient affected with ulcerative colitis and intestinal reactivation of cytomegalovirus infection. Medical alphabet. 2023;(34):6-10. (In Russ.) https://doi.org/10.33667/2078-5631-2023-34-6-10
Views:
316
Email this article 